1. Home
  2. News Archive

More News

2022 in Review: Viatris, Amgen Make Big Acquisitions and Enter Ophthalmic Market
2022 in Review: Viatris, Amgen Make Big Acquisitions and Enter Ophthalmic Market

Viatris and Amgen announced ophthalmic acquisitions in Q4-2022. Amgen’s purchase of Horizon Therapeutics was the largest biopharma acquisition of the year. In November 2022, Viatris announced its g...

2022 in Review: Large Ophthalmic Firms Increase Surgical Instrument Dominance
2022 in Review: Large Ophthalmic Firms Increase Surgical Instrument Dominance

The largest participants in the ophthalmic surgical instrument market increased their market dominance in 2022 through acquisition, consolidation, and product development. Once an industry of mainl...

2022 in Review: Competitors Near the Finish Line in Race for GA Treatment
2022 in Review: Competitors Near the Finish Line in Race for GA Treatment

The race for the first approved geographic atrophy (GA) treatment in the US heated up in 2022 as Iveric Bio and Apellis Pharmaceuticals closed in on the regulatory finish line. Iveric Bio announced...

2022 in Review: Bausch + Lomb Inches Toward Separation; Clarity Remains Elusive
2022 in Review: Bausch + Lomb Inches Toward Separation; Clarity Remains Elusive

Bausch + Lomb’s planned spinout in 2022, first made public in August 2020, seemed destined to provide clarity on the company’s future after an uneven nine years as a subsidiary of Bausch Health. Ye...

Harrow Acquires US Rights to Five Ophthalmic Drugs from Novartis, Will Pay up to $175 Million
Harrow Acquires US Rights to Five Ophthalmic Drugs from Novartis, Will Pay up to $175 Million

Harrow, of Nashville, Tennessee, reported Dec. 14 that it had agreed to acquire exclusive US rights to five ophthalmic drugs from Novartis: Ilevro, Nevanac, Vigamox, Maxidex, and Triesence. The mov...

STAAR Surgical’s Caren Mason to Retire; Tom Frinzi Appointed New CEO
STAAR Surgical’s Caren Mason to Retire; Tom Frinzi Appointed New CEO

STAAR Surgical announced Dec. 19 that President and Chief Executive Officer Caren Mason will be retiring on Dec. 31. STAAR’s Board of Directors has appointed ophthalmic industry executive Tom Frinz...

Market Scope’s Kristen Harmon Ingenito to Speak at Glaucoma 360
Market Scope’s Kristen Harmon Ingenito to Speak at Glaucoma 360

Join Market Scope's Kristen Harmon Ingenito for a special Glaucoma 360 presentation on the glaucoma market and the dizzying array of options that glaucoma specialists must sort through to choos...

Medicare Reimbursement Cuts for 2023 Reduced to 2 Percent
Medicare Reimbursement Cuts for 2023 Reduced to 2 Percent

The $1.7 trillion omnibus spending bill passed by Congress before Christmas 2022 and signed by President Biden on Dec. 29 reduces total cuts in Medicare physician reimbursement in 2023 to 2 percent...

Clinical Trial Updates for Ophthalmic Candidates, January 2023
Clinical Trial Updates for Ophthalmic Candidates, January 2023

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements. Date Company Candidate, Indication Milestone Notes Jan. 10 Glaukos iLution (GLK-301 pilocarp...

Emerging Companies Pursuing Ophthalmic Indications, January 2023
Emerging Companies Pursuing Ophthalmic Indications, January 2023

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease. Company Location About Amber Ophthalmics San Diego The company is developing Nexagon (lufepi...

Global Cornea Market Could Boom if New Technologies Satisfy Unmet Need
Global Cornea Market Could Boom if New Technologies Satisfy Unmet Need

The global market for cornea products remains largely underserved due to the reliance on human tissue and other obstacles. Several companies are developing products to mitigate these challenges. If...

Weekly Surgeon and Corporate Poll, January 2023
Weekly Surgeon and Corporate Poll, January 2023

January 2023 Ophthalmic News Briefs
January 2023 Ophthalmic News Briefs

Sweden’s Xbrane Biopharma and its partner Stada, of Germany, announced Jan. 16 that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) had granted marketing authorization for Ximlu...

Bausch + Lomb Acquires AcuFocus, Maker of Apthera Small-Aperture IOL
Bausch + Lomb Acquires AcuFocus, Maker of Apthera Small-Aperture IOL

Bausch + Lomb reported Jan. 17 that it had acquired AcuFocus, maker of the IC-8 Apthera small-aperture intraocular lens (IOL). No financial details on the deal were provided. AcuFocus, of Irvine, C...

UK Regulators Approve Ximluci, a Lucentis Biosimilar from Stada and Xbrane
UK Regulators Approve Ximluci, a Lucentis Biosimilar from Stada and Xbrane

Sweden’s Xbrane Biopharma and its partner Stada, of Germany, announced Jan. 16 that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) had granted marketing authorization for Ximlu...

Medicare Reimbursement Cuts for 2023 Reduced to 2 Percent
Medicare Reimbursement Cuts for 2023 Reduced to 2 Percent

The $1.7 trillion omnibus spending bill passed by Congress before Christmas 2022 and signed by President Biden on Dec. 29 reduces total cuts in Medicare physician reimbursement in 2023 to 2 percent...

Bausch + Lomb Reports US Recycling Benchmark; Horus Pharma Launches Green Partnership
Bausch + Lomb Reports US Recycling Benchmark; Horus Pharma Launches Green Partnership

Bausch + Lomb reported on Nov. 15, 2022, that two of its US recycling programs have collected 58.7 million units, or 356,723 pounds, of used contact lens and eye care and lens care materials. That ...

Keranova Touts Success of its PhotoEmulsification in Pivotal Trial, Readies to Seek CE Marking
Keranova Touts Success of its PhotoEmulsification in Pivotal Trial, Readies to Seek CE Marking

Keranova, of France, announced Jan. 11 that the company is ready to apply for CE marking for its FemtoMatrix robotic laser technology for cataract surgery. The company is developing a system design...

Pixium Says Newest Prima Can Restore Vision at 5 Times the Resolution of Current Implant
Pixium Says Newest Prima Can Restore Vision at 5 Times the Resolution of Current Implant

Pixium Vision, of France, reported Jan. 12 that the second generation of its Prima subretinal photovoltaic wireless implant for atrophic age-related macular degeneration (AMD) can restore vision at...

NGM Bio, Editas Shift Priorities, Seek Partners on Ophthalmic Programs
NGM Bio, Editas Shift Priorities, Seek Partners on Ophthalmic Programs

NGM Biopharmaceuticals and Editas Medicine recently announced shifts in their corporate strategies away from ophthalmology, and both companies said they were seeking partners to advance their ophth...

Stuart Therapeutics Expands Pipeline with Programs in DME, Myopia
Stuart Therapeutics Expands Pipeline with Programs in DME, Myopia

Stuart Therapeutics, of Florida, announced Jan. 9 that it had expanded its drug development pipeline, adding programs in diabetic macular edema (DME) and myopia. The company said preclinical studie...

4DMT Pursues DME Indication for Gene Therapy Candidate, Adds GA Candidate
4DMT Pursues DME Indication for Gene Therapy Candidate, Adds GA Candidate

4D Molecular Therapeutics announced Jan. 9 that it would expand its ophthalmic portfolio following early positive clinical data for its gene therapy candidate 4D-150 in wet age-related macular dege...

AcuFocus Begins Limited Release of Apthera IOL
AcuFocus Begins Limited Release of Apthera IOL

AcuFocus reported Jan. 6 that it had begun a limited commercial release of its IC-8 Apthera intraocular lens in the US. The lens gained FDA approval in July 2022. It also is available in Australia,...

Harrow Makes Fortisite Antibiotic Formulation Available for Office Stock
Harrow Makes Fortisite Antibiotic Formulation Available for Office Stock

Harrow, of Nashville, Tennessee, reported Jan. 5 that its Fortisite compounded antibiotic eye drop formulation—a combination of tobramycin 1.5% and vancomycin 5%—was available in the US from Harrow...

Glaukos Reports Positive Trial Results for Glaucoma, Corneal Candidates
Glaukos Reports Positive Trial Results for Glaucoma, Corneal Candidates

Glaukos provided several clinical trial updates Jan. 10 for its corneal and glaucoma candidates. The company saw positive results in a trial designed to evaluate the safety of a surgical exchange p...

Amber Ophthalmics Reports Positive Topline Phase II Data for Nexagon in PCED
Amber Ophthalmics Reports Positive Topline Phase II Data for Nexagon in PCED

Amber Ophthalmics, of San Diego, reported Jan. 9 that it saw positive topline results in a Phase II trial of Nexagon (lufepirsen ophthalmic gel) for persistent corneal epithelial defect (PCED) seco...

Coherus Licenses Eylea Biosimilar Candidate from Germany-Based Klinge
Coherus Licenses Eylea Biosimilar Candidate from Germany-Based Klinge

Coherus BioSciences, of Redwood City, California, reported Jan. 9 that it had agreed to acquire exclusive US rights to Eylea biosimilar candidate FYB203 from German company Klinge Biopharma. Klinge...

Acelyrin Acquires ValenzaBio and its Thyroid Eye Disease Candidate
Acelyrin Acquires ValenzaBio and its Thyroid Eye Disease Candidate

Acelyrin, of Los Angeles, announced Jan. 5 that it had acquired Maryland-based ValenzaBio, a privately held company developing therapies for autoimmune and inflammatory diseases. The deal was an al...

Curative Plans $6.8 Million Public Offering to Advance Metformin Formulation for AMD
Curative Plans $6.8 Million Public Offering to Advance Metformin Formulation for AMD

Curative Biotechnology, of Boca Raton, Florida, amended SEC paperwork on Jan. 9 indicating that it planned to make three financial moves ahead of advancing its four candidates—one ophthalmic—into c...

Intergalactic Therapeutics Appoints Theresa G.H. Heah, MD, MBA, as Chief Executive Officer
Intergalactic Therapeutics Appoints Theresa G.H. Heah, MD, MBA, as Chief Executive Officer

Intergalactic Therapeutics, a Boston-based non-viral gene therapy company, announced Jan. 6 that it had appointed Theresa G.H. Heah, MD, MBA, as chief executive officer. Heah succeeds Michael Ehler...

Orasis Submits NDA to US FDA for its Presbyopia Drop Candidate
Orasis Submits NDA to US FDA for its Presbyopia Drop Candidate

Orasis Pharmaceuticals announced Jan. 3 that it had submitted a new drug application (NDA) to the US FDA for CSF-1 (low dose pilocarpine hydrochloride 0.4%), a twice-daily presbyopia drop candidate...

US FDA Gives Green Light to Phase IIb Trial of Kala’s Corneal Candidate
US FDA Gives Green Light to Phase IIb Trial of Kala’s Corneal Candidate

Kala Pharmaceuticals announced Dec. 27 that the US FDA had accepted its investigational new drug (IND) application for KPI-012 for the treatment of persistent corneal epithelial defect (PCED). KPI-...

J&J Vision Launches TECNIS Synergy Toric II OptiBlue in India
J&J Vision Launches TECNIS Synergy Toric II OptiBlue in India

Johnson & Johnson Vision announced Dec. 28 that its presbyopia-correcting TECNIS Synergy Toric II OptiBlue lens had launched in India. The company introduced the OptiBlue extended depth of focus de...

Second Sight Ordered to Pay Pixium Vision Another €1.58M Over Scuttled Merger
Second Sight Ordered to Pay Pixium Vision Another €1.58M Over Scuttled Merger

Paris-based Pixium Vision reported Dec. 28 that a French court had ordered Second Sight Medical Products to pay Pixium an additional €1.58 million in costs and damages resulting from Second Sight s...

Mobius Adds US Patent for Injectable Mitomycin-C
Mobius Adds US Patent for Injectable Mitomycin-C

Mobius Therapeutics, of St. Louis, Missouri, reported Jan. 3 that it had been granted a new US patent for injected use of mitomycin-C in glaucoma surgery. Ophthalmic surgeons routinely apply mitomy...

Opus Genetics Acquires Two Retinal Gene Therapy Candidates from Iveric Bio
Opus Genetics Acquires Two Retinal Gene Therapy Candidates from Iveric Bio

Opus Genetics announced Dec. 28 that it had acquired the rights to two preclinical-stage AAV-based gene therapy candidates for inherited retinal diseases from Iveric Bio. Opus will develop the cand...

Rise in Lens-Based Procedures Will Push Retail Refractive Surgery Market to $12.0 Billion
Rise in Lens-Based Procedures Will Push Retail Refractive Surgery Market to $12.0 Billion

Market Scope forecasts that the global refractive surgery industry will generate $12.0 billion in total retail revenue in 2027—up from $8.9 billion in 2022—for a compound growth rate of 6.2 percent...

Joseph Papa to Stay with Bausch + Lomb Through at Least March 4
Joseph Papa to Stay with Bausch + Lomb Through at Least March 4

Bausch + Lomb reported Dec. 22, 2022, that chief executive officer Joseph Papa would continue serving in the role at least until March 4, 2023, under an amended separation agreement. Papa will leav...

Iveric President Pravin Dugel Joins Company Board
Iveric President Pravin Dugel Joins Company Board

Iveric Bio, of Parsippany, New Jersey, announced Jan. 3 that Pravin Dugel, MD, the company’s president, had joined the board of directors, as of Jan. 1. Iveric said Dugel had been instrumental in h...

EyePoint COO Jay Duker Adds Role of President
EyePoint COO Jay Duker Adds Role of President

EyePoint Pharmaceuticals reported Jan. 4 that Jay Duker, MD, would take on the role of president at the Watertown, Massachusetts, company, in addition to serving as chief operating officer. Duker h...

Apellis Appoints Retina Specialist Caroline Baumal, MD, as Chief Medical Officer
Apellis Appoints Retina Specialist Caroline Baumal, MD, as Chief Medical Officer

Apellis Pharmaceuticals, of Waltham, Massachusetts, announced Jan. 5 that retina specialist Caroline Baumal, MD, has joined the company as chief medical officer. Baumal replaces Federico Grossi, MD...

Iveric Bio Completes Rolling NDA Submission to US FDA for Avacincaptad Pegol in GA
Iveric Bio Completes Rolling NDA Submission to US FDA for Avacincaptad Pegol in GA

Iveric Bio announced Dec. 20 that it had submitted to the US FDA the third and final part of its new drug application (NDA) for rolling review of avacincaptad pegol, a complement C5 inhibitor in ge...

Eversight and Abu Dhabi Officials Partner to Establish UAE’s First Eye and Tissue Bank
Eversight and Abu Dhabi Officials Partner to Establish UAE’s First Eye and Tissue Bank

Global nonprofit eye bank Eversight and the Department of Health of Abu Dhabi are partnering to establish the first eye and tissue bank in the United Arab Emirates (UAE). The partnership was formal...

Scientists Say Eye Disease Drug May Also Help Fight COVID-19
Scientists Say Eye Disease Drug May Also Help Fight COVID-19

A research team led by University of California Los Angeles (UCLA) scientists found that the eye drug verteporfin stops replication of SARS-CoV-2, the virus that causes COVID-19, according to the N...

Aldeyra Submits NDA to US FDA for ADX‑2191 in Primary Vitreoretinal Lymphoma
Aldeyra Submits NDA to US FDA for ADX‑2191 in Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics announced Dec. 21 that it had submitted a new drug application (NDA) to the US FDA for ADX‑2191 (methotrexate injection) for primary vitreoretinal lymphoma, a rare but potentia...

European Regulators Accept Marketing Application for Outlook’s Lytenava in Wet AMD
European Regulators Accept Marketing Application for Outlook’s Lytenava in Wet AMD

Outlook Therapeutics announced Dec. 22 that the European Medicines Agency (EMA) had validated its marketing authorization application for ONS-5010 (bevacizumab-vikg) in wet age-related macular dege...

OKYO Gets Green Light from US FDA for Phase II Trial of OK-101 in Dry Eye
OKYO Gets Green Light from US FDA for Phase II Trial of OK-101 in Dry Eye

London’s OKYO Pharma announced Dec. 22 that the US FDA had cleared its investigational new drug (IND) application for topical dry eye treatment candidateOK-101. The company said it had designed its...

US FDA Grants Orphan Drug Designations to Ocugen Gene Therapy Candidate in RP, LCA
US FDA Grants Orphan Drug Designations to Ocugen Gene Therapy Candidate in RP, LCA

Ocugen announced Dec. 15 that the US FDA had granted orphan drug designations to OCU400—human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3)—for the treatment of retinitis pigmentos...

Brim Receives Orphan Drug Designation from US FDA for BRM424 in NK
Brim Receives Orphan Drug Designation from US FDA for BRM424 in NK

Brim Biotechnology, of Taiwan, announced Dec. 8 that the US FDA had granted orphan drug designation to its BRM424 for neurotrophic keratitis (NK), a rare degenerative eye disease that causes severe...

Rokid and Eyedaptic Launch EYE5 Smart Glasses for DR, AMD Patients
Rokid and Eyedaptic Launch EYE5 Smart Glasses for DR, AMD Patients

Rokid, an augmented reality glasses manufacturer, has partnered with Eyedaptic on EYE5, a low-vision aid for patients with central vision loss due to diabetic retinopathy (DR) and age-related macul...

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more